title: [Ten years progression-free survival obtained in a patient with mantle cell lymphoma].
abstract: Mantle cell lymphoma is a rare aggressive lymphoma derived from B cells, characterized by rapid progression and subsequent recurrence. It is considered to be an incurable disease, with exception of a certain group of patients treated with an autogenic stem cell transplantation. The mean survival time is three years, after applying the conventional regimen based on COP (cyclophosphamide, vincristine, prednisone) or CHOP chemotherapy (COP + doxorubicin). An addition of rituximab to CHOP regimen significantly prolongs progression-free survival. The present case reports ten years progression-free survival in a female patient with mantle cell lymphoma with baseline clinical stage IVB (MIPI 5), treated with nine courses of CHOP chemotherapy. Rituximab was added from 3 to 8 course. The complete clinical, radiological and histopathological response has been obtained.
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Elwira
authors.initials: E
authors.lastname: Wysokińska
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Kolak
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Elżbieta
authors.initials: E
authors.lastname: Starosławska
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Dariusz
authors.initials: D
authors.lastname: Kieszko
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Marzena
authors.initials: M
authors.lastname: Kamińska
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Dariusz
authors.initials: D
authors.lastname: Surdyka
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Mocarska
authors.affiliation: St. John's Cancer Center, Lublin, Poland.
authors.forename: Franciszek
authors.initials: F
authors.lastname: Burdan
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D011239:Prednisolone; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D000069283:Rituximab; D033581:Stem Cell Transplantation; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone
keywords: MCL; aggressive lymphoma; immunochemotherapy; mantle cell lymphoma; progression-free survival